Mateon Therapeutics Inc. | Key People and Executives
William D. Schwieterman
Chairman, President & Chief Executive Officer
Bobby W. Sandage
Independent Director
Donald R. Reynolds
Independent Director
David J. Chaplin
Independent Director
Simon C. Pedder
Independent Director
William D. Schwieterman
Chairman, President & Chief Executive Officer
Matthew M. Loar
CFO & Head-Business Development
Kathleen M. Lee
Vice President-Chemistry, Manufacturing & Controls
Bobby W. Sandage
Independent Director
Donald R. Reynolds
Independent Director
David J. Chaplin
Independent Director
Simon C. Pedder
Independent Director
| Address |
701 Gateway Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.mateon.com |
| Updated |
07/08/2019 |
| Mateon Therapeutics, Inc. operates as a clinical stage biopharmaceutical company which develops small molecule injectable drugs for the treatment of cancer. The firm develops OXi4503 for the treatment of acute myeloid leukemia. The OXi4503 has dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction. |
